Clinical Trial Details


Research Study Summary

Ankylosing Spondylitis Study


Ankylosing Spondylitis is painful and debilitating form of arthritis that affects the spine. The purpose of this study is to evaluate the effectiveness of the drug ixekizumab (LY2439821) compared to placebo over a 16 week period in patient's with radiographic axial spondyloarthritis (rad-axSpA). If you have been diagnosed with this painful condition, please contact our office. Compensation for time and travel may be available for this study.

To see if you qualify click here.

To Learn more

CW ID: 225126
Date Last Changed: June 26, 2017

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Lead Sponsor
16 Weeks
Facility Type


Qualified Subjects must have a current diagnosis of Ankylosing Spondylitis, history of back pain for at least 3 months and prior treatment for AS

More Info

Those who qualify may receive care from a board certified physician at not cost, access to possible new treatment and compensation for time and travel.


To see if you qualify click here.

Jen Molnar, Study Manager
New England Research Associates, LLC
5520 Park Avenue Suite M2-100
Trumbull, CT 06611
Phone: 203-374-9816
Fax: 203-502-8490

View Map

Research Center Information:

New England Research Associates, LLC

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.